Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3176676 | 1.00 | CYSLTR1 (0.45) | CYSLTR1MRGPRX4SMN1; SMN2TP53RAB9A | |
| SCHEMBL13531014 | 0.88 | KMT2A (0.51) | SMN1; SMN2RAB9ANPC1POLBCASP3 | |
| SCHEMBL13529582 | 0.87 | RAB9A (0.40) | SMN1; SMN2TP53RAB9ANPC1POLB | |
| SCHEMBL12150147 | 0.79 | HTT (0.43) | SMN1; SMN2RAB9ANPC1POLBKMT2A | |
| SCHEMBL13529949 | 0.79 | CYP3A4 (0.53) | TP53ALDH1A1 | |
| SCHEMBL29960309 | 0.79 | CYSLTR1 (0.51) | CYSLTR1MRGPRX4SMN1; SMN2TP53RAB9A | |
| SCHEMBL31589814 | 0.79 | CYSLTR1 (0.53) | CYSLTR1MRGPRX4SMN1; SMN2TP53RAB9A | |
| SCHEMBL7949450 | 0.79 | CYSLTR1 (0.53) | CYSLTR1MRGPRX4SMN1; SMN2TP53RAB9A | |
| SCHEMBL31442462 | 0.77 | SMN1; SMN2 (0.58) | CYSLTR1MRGPRX4SMN1; SMN2TP53RAB9A | |
| SCHEMBL644216 | 0.77 | SMN1; SMN2 (0.58) | CYSLTR1MRGPRX4SMN1; SMN2TP53RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-20090181930-A1 | KINASE INHIBITORY PHOSPHONATE ANALOGS | CANNIZZARO CARINA | 2009-07-16 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7417055-B2 | Kinase inhibitory phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-20060079478-A1 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. | 2006-04-13 | — | — | US | disclosed |
| EP-1620109-A2 | KINASE INHIBITOR PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2006-02-01 | — | — | EP | disclosed |
| EP-1617848-A2 | ANTI-CANCER PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20050261253-A1 | Kinase inhibitory phosphonate analogs | GILEAD SCIENCES, INC. | 2005-11-24 | — | — | US | disclosed |
| WO-2004096235-A2 | ANTI-CANCER PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096234-A2 | KINASE INHIBITOR PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261253-A1 | Kinase inhibitory phosphonate analogs | PIK3CA, PNKP, PIK3CB | CYSLTR1 4456/4885MRGPRX4 4392/4885SMN1; SMN2 4005/4885 |
| US-20060079478-A1 | Anti-cancer phosphonate analogs | PIK3CA, PHOSPHO1, PTEN | CYSLTR1 4673/4885MRGPRX4 4453/4885SMN1; SMN2 3947/4885 |
| US-20090181930-A1 | KINASE INHIBITORY PHOSPHONATE ANALOGS | PIK3CA, PNKP, PIK3CB | CYSLTR1 4456/4885MRGPRX4 4392/4885SMN1; SMN2 4005/4885 |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | PIK3CA, PHOSPHO1, PTEN | CYSLTR1 4673/4885MRGPRX4 4453/4885SMN1; SMN2 3947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.